These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17990373)

  • 1. Nonalcoholic fatty liver disease: an increasingly common cause of liver disease among HIV-infected persons?
    Crum-Cianflone NF
    AIDS Read; 2007 Oct; 17(10):513-8. PubMed ID: 17990373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease: from clinical recognition to treatment.
    Sevastianos VA; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):59-79. PubMed ID: 19072371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime.
    Blonsky JJ; Harrison SA
    Aliment Pharmacol Ther; 2008 May; 27(10):855-65. PubMed ID: 18315584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trials and tribulations of the treatment of nonalcoholic fatty-liver disease.
    Gan SK; Adams LA; Watts GF
    Curr Opin Lipidol; 2008 Dec; 19(6):592-9. PubMed ID: 18957882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.
    Borghi V; Puoti M; Mussini C; Bellelli S; Angeletti C; Sabbatini F; Prati F; Cossarizza A; Esposito R
    Antivir Ther; 2008; 13(8):1057-65. PubMed ID: 19195331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia.
    Day L; Shikuma C; Gerschenson M
    Mitochondrion; 2004 Jul; 4(2-3):95-109. PubMed ID: 16120375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease.
    Spruss A; Bergheim I
    J Nutr Biochem; 2009 Sep; 20(9):657-62. PubMed ID: 19679262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver steatosis in HIV-infected patients.
    Piroth L
    AIDS Rev; 2005; 7(4):197-209. PubMed ID: 16425960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatic steatosis: an emerging cause of cirrhosis in HIV patients].
    Loulergue P; Callard P; Bonnard P; Pialoux G
    Pathol Biol (Paris); 2006 Dec; 54(10):587-90. PubMed ID: 17027188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
    Boppidi H; Daram SR
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current concepts in the pathogenesis of nonalcoholic fatty liver disease.
    Méndez-Sánchez N; Arrese M; Zamora-Valdés D; Uribe M
    Liver Int; 2007 May; 27(4):423-33. PubMed ID: 17403181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C infection and nonalcoholic fatty liver disease.
    Cheung O; Sanyal AJ
    Clin Liver Dis; 2008 Aug; 12(3):573-85, viii-ix. PubMed ID: 18625429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.
    Rodríguez-Torres M; Govindarajan S; Solá R; Clumeck N; Lissen E; Pessôa M; Buggisch P; Main J; Depamphilis J; Dieterich DT
    J Hepatol; 2008 May; 48(5):756-64. PubMed ID: 18314217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric nonalcoholic fatty liver disease.
    Lerret SM; Skelton JA
    Gastroenterol Nurs; 2008; 31(2):115-9. PubMed ID: 18391799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.